Recro Pharma Inc. (REPH)’s Financial Results Comparing With Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)

As Biotechnology businesses, Recro Pharma Inc. (NASDAQ:REPH) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), are affected by compare. This especially applies to their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Recro Pharma Inc. 14 0.00 19.48M -3.27 0.00
Pieris Pharmaceuticals Inc. 4 0.00 41.48M -0.54 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 shows the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Recro Pharma Inc. 139,441,660.70% 0% -40%
Pieris Pharmaceuticals Inc. 1,156,172,478.19% -64.6% -19.4%

Risk & Volatility

A -0.27 beta indicates that Recro Pharma Inc. is 127.00% less volatile compared to S&P 500. Competitively, Pieris Pharmaceuticals Inc.’s beta is 1.21 which is 21.00% more volatile than S&P 500.

Liquidity

3.6 and 3.2 are the respective Current Ratio and a Quick Ratio of Recro Pharma Inc. Its rival Pieris Pharmaceuticals Inc.’s Current and Quick Ratios are 3 and 3 respectively. Recro Pharma Inc. has a better chance of clearing its pay short and long-term debts than Pieris Pharmaceuticals Inc.

Analyst Recommendations

Recro Pharma Inc. and Pieris Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Recro Pharma Inc. 0 0 1 3.00
Pieris Pharmaceuticals Inc. 0 1 0 2.00

Recro Pharma Inc.’s consensus price target is $19, while its potential upside is 14.05%. On the other hand, Pieris Pharmaceuticals Inc.’s potential upside is 27.23% and its consensus price target is $5. The results from earlier shows that analysts view suggest that Pieris Pharmaceuticals Inc. seems more appealing than Recro Pharma Inc.

Insider and Institutional Ownership

The shares of both Recro Pharma Inc. and Pieris Pharmaceuticals Inc. are owned by institutional investors at 71.4% and 61.7% respectively. Insiders owned 1.8% of Recro Pharma Inc. shares. Insiders Comparatively, owned 0.23% of Pieris Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Recro Pharma Inc. -2.04% -5.88% 5.96% 21.52% 88.61% 35.21%
Pieris Pharmaceuticals Inc. 20.88% 17.77% 84.56% 106.77% 3.38% 106.77%

For the past year Recro Pharma Inc.’s stock price has smaller growth than Pieris Pharmaceuticals Inc.

Summary

Pieris Pharmaceuticals Inc. beats Recro Pharma Inc. on 7 of the 11 factors.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. Its lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. The company also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain. It also provides contract development and manufacturing services. It has a license agreement with Orion Corporation for the development and commercialization of Non-Injectable Dexmedetomidine. The company focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases. It has strategic partnership agreements with Allergan, Inc.; Sanofi Group; Daiichi Sankyo Company Limited; F.Hoffmann- La Roche Ltd. and Hoffmann- La Roche Inc.; ASKA Pharmaceutical Co., Ltd; and Les Laboratoires Servier and Institut de Recherches Internationales. The company also has a research and licensing agreement with Technische Universität München; and a collaboration agreement with AstraZeneca. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.